Pharmacopeia

CWP-0173

MOXIFLOXACIN

Anti-infectives · Anti-infectives · Level 3

Core pharmacology

Class Group

ANTIBIOTIC:
QUINOLONE

Introduction

Quinolone

Presentation

PO and IV

Mechanism of action

Bacteriocidal antimicrobials that block DNA replication by blocking tropoisomerase enzymes, which are essential for the supercoiling, replication and separation of circular bacterial DNA

Antimicrobial Spectrum

1. Gram positives
- Better strep pneumonia cover
2. Gram negatives
- Including salmonella, Neisseria, pseudomonas, E. Coli
3. Anaerobes
- Modest including B. Fragilis
4. Atypicals
Legionella, mycoplasma, Rickettsia, Chlamydia

Resistance Mechanism

Alteration in target enzyme – changes to the DNA binding surface of DNA supergyrase infers resistance
Alteration in drug entry – altered expression of outer membrane porin proteins that form channels for passive diffusion of moxifloxacin
Increase in efflux of drug – expression of nonspecific energy dependent efflux pumps which remove drug

Adverse Effects Toxicity

1. CNS Toxicity- GABA antagonists and may precipitate seizures in epileptic patients, particularly in presence of NSAIDs
2. Tendonitis and tendon rupture
3. QT prolongation- Low risk of Torsade’s in absence of other predisposing factors
4. Hemolysis in G6PD
5. Photosensitivity
6. Arthralgias and cartilage toxicity (generally avoided in children)
7. Dysglycaemia (hyper and hypoglycaemia)

Absorption

90% oral absorption

Coadministration of calcium or magnesium reduces absorption

Distribution

High CSF and tissue penetration

Protein binding

30% PB

Metabolism

Little hepatic metabolism

Excretion

Renal excretion

Half-life

T1/2= 12 hours
Renal dose adjustment not required

Anti-infectives · Anti-infectives

Legacy Cicm Level

Level 3

Legacy Cicm Level

Level 1